Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, et al.
Science (2020) Vol. 368, Iss. 6486
Open Access | Times Cited: 265

Showing 26-50 of 265 citing articles:

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
Lotte van Beek, Éilís McClay, Saleha Patel, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5112-5112
Open Access | Times Cited: 66
PARP1: Structural insights and pharmacological targets for inhibition
Jacob O. Spiegel, Bennett Van Houten, Jacob D. Durrant
DNA repair (2021) Vol. 103, pp. 103125-103125
Open Access | Times Cited: 61
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Shuangying Li, Liangliang Wang, Yuanyuan Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 60
Mechanism and function of DNA replication‐independent DNA‐protein crosslink repair via the SUMO‐RNF4 pathway
Julio C.Y. Liu, Ulrike Kühbacher, Nicolai Balle Larsen, et al.
The EMBO Journal (2021) Vol. 40, Iss. 18
Open Access | Times Cited: 56
HPF1 dynamically controls the PARP1/2 balance between initiating and elongating ADP-ribose modifications
Marie-France Langelier, Ramya Billur, Aleksandr Sverzhinsky, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 56
Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery
Élise Rouleau-Turcotte, Dragomir B. Krastev, Stephen J. Pettitt, et al.
Molecular Cell (2022) Vol. 82, Iss. 16, pp. 2939-2951.e5
Open Access | Times Cited: 42
PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
Xiaohui Lin, Wenxia Jiang, Johannes Rudolph, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 7, pp. 3958-3973
Open Access | Times Cited: 41
Updated protein domain annotation of the PARP protein family sheds new light on biological function
Marcin J. Suskiewicz, Deeksha Munnur, Øyvind Strømland, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 15, pp. 8217-8236
Open Access | Times Cited: 33
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
Marie-France Langelier, Xiaohui Lin, Shan Zha, et al.
Science Advances (2023) Vol. 9, Iss. 12
Open Access | Times Cited: 29
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Xiaoyu Fu, Ping Li, Qi Zhou, et al.
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 306-320
Open Access | Times Cited: 26
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance
Petar-Bogomil Kanev, Aleksandar Atemin, Stoyno Stoynov, et al.
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 2-18
Open Access | Times Cited: 22
ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification
Élise Rouleau-Turcotte, John M. Pascal
Journal of Biological Chemistry (2023) Vol. 299, Iss. 12, pp. 105397-105397
Open Access | Times Cited: 22
Parthanatos: Mechanisms, modulation, and therapeutic prospects in neurodegenerative disease and stroke
Yang Liu, Lauren Guttman, Valina L. Dawson, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116174-116174
Closed Access | Times Cited: 12
A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells
Petar-Bogomil Kanev, Sylvia Varhoshkova, Irina Georgieva, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114234-114234
Open Access | Times Cited: 10
Recent advances in c-Met-based dual inhibitors in the treatment of cancers
Fanqi Jin, Yi‐Han Lin, Yuan Weidong, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116477-116477
Closed Access | Times Cited: 9
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
Zhengping Shao, Brian J. Lee, Élise Rouleau-Turcotte, et al.
Nucleic Acids Research (2020) Vol. 48, Iss. 17, pp. 9694-9709
Open Access | Times Cited: 69
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
Susana Banerjee, Antonio González-Martı́n, Philipp Harter, et al.
ESMO Open (2020) Vol. 5, Iss. 6, pp. e001110-e001110
Open Access | Times Cited: 65
PARP Inhibitors in Cancer Diagnosis and Therapy
Chung Ying Chan, Kel Vin Tan, Bart Cornelissen
Clinical Cancer Research (2020) Vol. 27, Iss. 6, pp. 1585-1594
Open Access | Times Cited: 61
Human MYC G-quadruplex: From discovery to a cancer therapeutic target
Wenmeng Wang, Shuangli Hu, Yaru Gu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188410-188410
Closed Access | Times Cited: 60
PARP1 catalytic variants reveal branching and chain length-specific functions of poly(ADP-ribose) in cellular physiology and stress response
L. B. Aberle, Annika Krüger, Julia M. Reber, et al.
Nucleic Acids Research (2020) Vol. 48, Iss. 18, pp. 10015-10033
Open Access | Times Cited: 59
The Chromatin Response to Double-Strand DNA Breaks and Their Repair
Radoslav Aleksandrov, Rossitsa Hristova, Stoyno Stoynov, et al.
Cells (2020) Vol. 9, Iss. 8, pp. 1853-1853
Open Access | Times Cited: 59
Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
Chris A. Brosey, Jerry H. Houl, Panagiotis Katsonis, et al.
Progress in Biophysics and Molecular Biology (2021) Vol. 163, pp. 171-186
Open Access | Times Cited: 54
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
Johannes Rudolph, Genevieve Roberts, Karolin Luger
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 52
Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Desh Deepak Singh, Amna Parveen, Dharmendra Kumar Yadav
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1512-1512
Open Access | Times Cited: 52
Activation of PARP2/ARTD2 by DNA damage induces conformational changes relieving enzyme autoinhibition
Ezeogo Obaji, Mirko M. Maksimainen, Albert Galera‐Prat, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 50

Scroll to top